Corporate venture investors stay strong
The big names in biotech venture investment might be pulling back, but funds backed by pharma are still out there.
Unpacking Royalty Pharma
The serial acquirer of royalty interests is coming into its own, but the secret to its success lies in cystic fibrosis.
Theravance gets a fresh start
Meanwhile, Royalty Pharma bets that Trelegy will do better than the sellside expects.
Teneo’s heavy chain success keeps on delivering
Yesterday’s takeout of Teneotwo came amid notable big pharma interest in the geeky science behind heavy chain-only antibodies.
